

COMPLETE IF KNOWN

Application Number	10/527,561
---------------------------	------------

Filing Date	March 11, 2005
--------------------	-----------------------

First Named Inventor	I.E. Kopka et al.
-----------------------------	-------------------

Group Art Unit

Examiner Name

Attorney Docket Number 21204P

1 of 4

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number <i>(if known)</i>		
W			EP 0 576 357	Sanofi	03/05/1997
			EP 0 656 354	Sanofi	06/04/1997
			WO 2004/111039	AstraZeneca AB	12/23/2004
			WO 2004/111033	AstraZeneca AB	12/23/2004
			WO 2004/111034	AstraZeneca AB	12/23/2004
			WO 2004/111038	AstraZeneca AB	12/23/2004
			WO 2005/000817	Sanofi-Aventis	01/06/2005
			WO 2004/037823	Pfizer Products Inc.	05/06/2004
			WO 2004/012671	Merck & Co., Inc.	02/12/2004
W			WO 2004/110453	Pfizer Products Inc.	12/23/2004

**Examiner
Signature**

1/ Palasumbanan

Date Considered


10/30/07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form * LDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

COMPLETE IF KNOWN



(use ~~a~~ many sheets as necessary)

Sheet

3

of

4

10/527,561

March 11, 2005

I.E. Kopka et al.

1

1

21204P

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number <small>(if known)</small>		
W			WO 2004/052864	Pfizer Products Inc.	06/24/2004
			WO 98/37061	Bayer Aktiengesellschaft	08/27/1998
			WO 03/002114	AB Science	01/09/2003
			WO 03/006007	Research & Innovation Soc. Coop. A R.L.	01/23/2003
			WO 98/32441	Sanofi	07/30/1998
			WO 01/58450	Sanofi-Synthelabo	08/16/2001
			WO 2005/009479	Merck & Co., Inc.	02/03/2005
W			WO 03/000787	The Nisshin Oil Mills, Ltd./Ina Food Industry Co., Ltd.	03/01/2003

**Examiner
Signature**

1/ Polasubaner

Date Considered

10 | 30 | 07

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO			COMPLETE IF KNOWN		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use many sheets as necessary)			Application Number	10/527,561	
			Filing Date	March 11, 2005	
			First Named Inventor	I.E. Kopka et al.	
			Group Art Unit		
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	21204P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
M	AA	Le Foll et al., J. Pharm. & Exper. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
M	AB	Lange et al., J. Med. Chem., pp. A-P , "Bioisosteric replacements of the pyrazole moiety of rimonabant ... 48(6), 1523-1539, 2005"
M	AC	Piomelli et al., Trends in Pharma. Sci., Vol. 21 (2000), pp. 218-224, "The endocannabinoid system as a target for therapeutic drugs"
M	AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
M	AE	Xiang et al., Ann. Reports in Med. Chem., Vol. 34 (1999), pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
M	AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
M	AG	Rinaldi-Carmona et al., Life Sciences, Vol. 56 (1995), pp. 1941-1947, "Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"
M	AH	Rinaldi-Carmona et al., FEBS Letters, Vol. 350 (1994), pp. 250-244, "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"
M	AI	Hetzheim et al., Pharmazie, Vol. 40(1) (1985), pp. 17-20, "Ringtransformation von O,N-heterocyclen"

Examiner Signature	<i>V. Balesar</i>	Date Considered	10/30/07
--------------------	-------------------	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003